Olema Pharmaceuticals (NASDAQ:OLMA) is one of the 17 biotechnology stocks with more than 50% upside. On February 11, Laura Prendergast of Stifel Nicolaus initiated coverage of Olema Pharmaceuticals ...
Olema Pharmaceuticals (NASDAQ:OLMA) is focused on developing endocrine therapies aimed at improving outcomes for patients ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...
SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...
Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...
Olema’s restructuring announced today is the result of a strategic decision to focus resources on the late-stage clinical development of OP-1250, which includes the initiation of the company’s first ...
Olema Pharmaceuticals, Inc. announced that its President and CEO, Sean P. Bohen, will present at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 10:30 a.m. ET. The presentation ...
Olema Pharmaceuticals, Inc. surged over 135% after Roche's positive SERD breast cancer data, boosting optimism for Olema's similar drug, palazestrant. OLMA is advancing palazestrant in late-stage ...
Olema is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).
Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of the best hot stocks to invest in. On October 8, Guggenheim initiated coverage of Olema Oncology with a Buy rating and $20 price target. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results